On 30 November 2012, the final stage in the transformation from Nycomed Australia to Takeda Australia was completed, with the Company operating officially under the name Takeda Pharmaceuticals Australia Pty Ltd.
The Nycomed history in Australia dates back to 2001 and globally it stretches back to Norway in 1874 when the Company was an agent of foreign pharmaceutical products. Nycomed was acquired by Takeda in October 2011.
Takeda, with a long and rich history spanning 231 years, is Japan’s largest pharmaceutical company and the 12th largest worldwide. Takeda’s mission is to ‘strive towards better health for people worldwide through leading innovation in medicine.’ To achieve this goal, the Company is pursuing new drug discovery that overcomes the barriers to technical innovation currently seen in the pharmaceutical industry in order to develop a strong pipeline of products that offer outstanding efficacy and safety for people worldwide.
We are a young and dynamic company in Australia with a focus on innovation and an expanding product portfolio servicing a diversity of stakeholders, partners and customers in the healthcare sector. A proven track record of success under continuously evolving market dynamics demonstrates our determination and ability to achieve results.
About Takeda - Who we are
As the largest pharmaceutical company in Japan and a leader in the global industry, Takeda’s mission is to strive toward better health for patients worldwide through leading innovation in medicine. It has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China.
What we do
With a broad portfolio of products and a powerful pipeline, we work in a wide range of therapeutic areas, particularly gastroenterology, respiratory and tissue management.
Where we work
Takeda has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China.